Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Prognostic Value of End of Treatment FDG-PET Scan in T-Cell Lymphoma, a 20-Year Single Institution Study

Enrico Derenzini, MD PhD, Angela Gueli, MD, Safaa Ramadan, PhD MD, Anna Vanazzi, MD, Simona Sammassimo, MD, Federica Gigli, MD, Niccolo' Frungillo, MD, Riccardo Bruna, MD, Alberto Agazzi, MD, Alberto De Crescenzo, MD, Rocco Pastano, MD, Laura L Travaini, MD, Chiara Grana, MD, Laszlo Daniele, MD, William Arcese, Corrado Tarella, MD

Blood (2016) 128 (22): 3003.

https://doi.org/10.1182/blood.V128.22.3003.3003

Published: 2016

Journal Articles

Whole Body Magnetic Resonance Imaging with Diffusion Weighted Imaging Is a Valuable Alternative to Contrast-Enhanced Computed Tomography for the Initial Staging in Hodgkin’s and Non-Hodgkin’s Lymphoma

Annalisa Balbo-Musetto, MD, Riccardo Bruna, MD, Angela Gueli, MD, Chiara Saviolo, MD, Massimo Petracchini, MD, Daniela Gottardi, MD, Alberto De Crescenzo, MD, Stefano Cirillo, MD, Corrado Tarella, MD

Blood (2014) 124 (21): 1278.

https://doi.org/10.1182/blood.V124.21.1278.1278

Published: 2014

Journal Articles

The Peripheral Blood Lymphocyte to Monocyte Ratio At Diagnosis Is a Potent Outcome Predictor in Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Long-Term Analysis On 973 Patients Receiving Chemotherapy with or without Rituximab

Alessandro Rambaldi, MD, Cristina Boschini, Federica Delaini, BiolSC, Elena Oldani, BiolSC, Andrea Rossi, MD, Anna Maria Barbui, MD, Giuseppe Gritti, MD, Daniele Caracciolo, MD, Marco Ladetto, MD, Angela Gueli, MD, Alberto De Crescenzo, MD, Roberto Passera, PhD, Liliana Devizzi, MD, Alessandro M. Gianni, MD, Corrado Tarella, MD

Blood (2012) 120 (21): 1553.

https://doi.org/10.1182/blood.V120.21.1553.1553

Published: 2012

Journal Articles

Early and Permanent Telomere Shortening in Bone Marrow-Derived Cells Following Chemotherapy: A Parallel Study In Vivo in Lymphoma Patients and In Vitro in Cultured Mesenchymal Stem Cells

Angela Gueli, MD, Marco Ruella, MD, Alessandra Risso, PhD, Tiziana Spatola, PhD, Hui Jing Hu, MD, Daniela Gottardi, MD, Alberto De Crescenzo, MD, Stefano Buttiglieri, PhD, Corrado Tarella, MD

Blood (2011) 118 (21): 1620.

https://doi.org/10.1182/blood.V118.21.1620.1620

Published: 2011

Journal Articles

Lenalidomide as Single Agent to Control Minimal Residual Disease in Chronic Lymphocytic Leukemia In First Complete Remission: Report of Three cases

Alberto De Crescenzo, MD, Marco Ruella, MD, Daniela Gottardi, MD, Giuseppina Prato, PhD, Massimo Geuna, PhD, Angela Gueli, MD, Corrado Tarella, MD

Blood (2010) 116 (21): 4640.

https://doi.org/10.1182/blood.V116.21.4640.4640

Published: 2010

Journal Articles

A Recent Update of Three Consecutive Prospective Trials with High-Dose Therapy and Autograft, without or with Rituximab, as Primary Treatment for Advanced-Stage Follicular Lymphoma (FL) Shows a Sizeable Group of Patients Surviving in Continuous Complete Remission up to 16 Years After the End of Treatment: Should We Still Consider FL An Incurable Disease ?.

Blood (2009) 114 (22): 882.

https://doi.org/10.1182/blood.V114.22.882.882

Published: 2009

Journal Articles

Dexamethasone, Cytarabine and Cisplatin or Oxaliplatin Schedule (DHAP or Ox-DHA) Is Effective and Widely Applicable in Chronic Lymphocytic Leukemia and Waldenström Macroglobulinemia.

Marco Ruella, MD, Irene Ricca, MD, Angela Gueli, MD, Daniela Gottardi, MD, Daniele Caracciolo, MD, Luciana Bergui, MD, Paolo Gavarotti, MD, Alberto De Crescenzo, MD, Lucia Farina, Paolo Corradini, MD, Corrado Tarella, MD

Blood (2009) 114 (22): 3434.

https://doi.org/10.1182/blood.V114.22.3434.3434

Published: 2009

Journal Articles

Sequential Brief Chemo-Immunotherapy FND + Rituximab in Elderly Patients with Advanced Stage Follicular Lymphoma (FL): High Clinical and Molecular Remission Rate Associated with a Prolonged Failure-Free Survival.

Blood (2004) 104 (11): 1320.

https://doi.org/10.1182/blood.V104.11.1320.1320

Published: 2004

Journal Articles

High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO)

Blood (2002) 100 (5): 1559–1565.

https://doi.org/10.1182/blood-2002-02-0621

Published: 2002

NARROW

Prognostic Value of End of Treatment FDG-PET Scan in T-Cell Lymphoma, a 20-Year Single Institution Study

Whole Body Magnetic Resonance Imaging with Diffusion Weighted Imaging Is a Valuable Alternative to Contrast-Enhanced Computed Tomography for the Initial Staging in Hodgkin’s and Non-Hodgkin’s Lymphoma

The Peripheral Blood Lymphocyte to Monocyte Ratio At Diagnosis Is a Potent Outcome Predictor in Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Long-Term Analysis On 973 Patients Receiving Chemotherapy with or without Rituximab

Early and Permanent Telomere Shortening in Bone Marrow-Derived Cells Following Chemotherapy: A Parallel Study In Vivo in Lymphoma Patients and In Vitro in Cultured Mesenchymal Stem Cells

Lenalidomide as Single Agent to Control Minimal Residual Disease in Chronic Lymphocytic Leukemia In First Complete Remission: Report of Three cases

Dexamethasone, Cytarabine and Cisplatin or Oxaliplatin Schedule (DHAP or Ox-DHA) Is Effective and Widely Applicable in Chronic Lymphocytic Leukemia and Waldenström Macroglobulinemia.

Sequential Brief Chemo-Immunotherapy FND + Rituximab in Elderly Patients with Advanced Stage Follicular Lymphoma (FL): High Clinical and Molecular Remission Rate Associated with a Prolonged Failure-Free Survival.

High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only